EUVIMEDEUVIMED entdecken
Crossref

Bayesian sequential decision-making for rare disease clinical trials

Yuan Gao iD, Jianling Bai iD, Feng Chen iD

Technology and Health Care · 2025

DOI: 10.1177/09287329251344056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Technology and Health Care, 2025. Verfasst von Yuan Gao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, School of Public Heath, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Rare Diseases, Decision Making, Clinical Trials as Topic. Die Arbeit nennt 66 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rare disease clinical trials face challenges due to limited sample sizes and ethical imperatives to minimize futile treatments. Bayesian sequential design dynamically optimizes decisions under uncertainty, offering efficiency gains over traditional fixed-sample approaches.

Methods

Propose a framework integrating sequential Bayes factor and adaptive stopping rules for trials with binary endpoint. Bayesian posterior probabilities define early termination thresholds (superiority/futility), while Bayes Factor Design Analysis validates trial feasibility. Sequential Bayes factor updates iteratively guide interim decisions based on evidence strength.

Results

The approach enables earlier trial termination (for superiority or futility), reducing sample size, time, and costs. Patients avoid unnecessary exposure to futility treatments, while results remain interpretable even if thresholds are unmet.

Conclusion

The primary goal is to confirm treatment efficacy earlier, enabling trials to be stopped promptly for either superiority or futility treatments. This strategy reduces sample size, time, and financial costs, and prevents patient exposure to futile treatments. Moreover, the study aims to promote the adoption of Bayesian sequential decision-making, thereby accelerating rare disease clinical trial approvals and drug marketing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rare DiseasesDecision MakingClinical Trials as TopicBayes TheoremHumansResearch DesignSample SizeMedical Futility

Stichwörter der Autor:innen

Bayes FactorBayes Factor Design AnalysisBayesian sequential decisionSequential Bayes Factor Testrare disease clinical trials

Autor:innen und Institutionen

  • Department of Biostatistics, School of Public Heath, Nanjing Medical University, Nanjing, China.

ORCID-Profile: Yuan Gao, Jianling Bai, Feng Chen

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Gao, Y., Bai, J., & Chen, F. (2025). Bayesian sequential decision-making for rare disease clinical trials. Technology and Health Care. https://doi.org/10.1177/09287329251344056

Vancouver

Gao Y, Bai J, Chen F. Bayesian sequential decision-making for rare disease clinical trials. Technology and Health Care. 2025. doi:10.1177/09287329251344056

BibTeX
@article{Gao2025,
  author = {Gao, Yuan and Bai, Jianling and Chen, Feng},
  title = {Bayesian sequential decision-making for rare disease clinical trials},
  journal = {Technology and Health Care},
  year = {2025},
  doi = {10.1177/09287329251344056}
}
Kostenlos starten →